XML 23 R11.htm IDEA: XBRL DOCUMENT v3.19.2
SHAREHOLDERS` EQUITY
12 Months Ended
May 31, 2019
Stockholders' Equity Note [Abstract]  
Stockholders' Equity Note Disclosure [Text Block]

5.    SHAREHOLDERS' EQUITY


STOCK OPTION AND RESTRICTED STOCK PLANS


 In August 2010, the Company adopted a stock option and restricted stock plan (the "2010 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2010.  The 2010 Plan expires in December 2020. Options granted under the 2010 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.


In December 2014, the Company adopted a stock option and restricted stock plan (the "2014 Plan") which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 850,000 shares of the Company's unissued common stock may be granted to affiliates, employees or consultants of the Company. This plan was approved by shareholders in December 2014.  The 2014 Plan expires in December 2024. Options granted under the 2014 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.


In December 2017, the Company adopted a stock option and restricted stock plan (the “2017 Plan”) which provides that non-qualified options and incentive stock options and restricted stock covering an aggregate of 900,000 shares of the Company’s unissued common stock may be granted to affiliates, employees or consultants of the Company.  This plan was approved by shareholders in December 2017.  The 2017 Plan expires in December 2027.  Options granted under the 2017 Plan will be granted at prices not less than 80% of the then fair market value of the common stock and will expire not more than 10 years after the date of grant.


Stock option expense during fiscal 2019 was $151,224. This included, by department, $3,714 for research and development, $143,299 in administrative, $4,163 in sales and marketing and $49 in Mexico. In fiscal 2018 stock option expense was $18,473. This included $2,486 in research and development, $14,613 in administrative, $1,223 in sales and marketing and $151 in Mexico.


Activity as to aggregate stock options outstanding is as follows:


 

NUMBER OF

STOCK OPTIONS

 

EXERCISE

PRICE

RANGE

PER SHARE

 

WEIGHTED
AVERAGE

EXERCISE PRICE

                                                            

 

 

Options outstanding at May 31, 2017

897,000

 

$0.71-$1.61

 

$

0.98

Options granted

287,000

 

$2.41-$3.90

 

$

3.63

Options exercised

(34,750)

 

$0.71-$1.04

 

$

0.80

Options canceled or expired

(10,625)

 

$0.71-$2.41

 

$

1.44

Options outstanding at May 31, 2018

1,138,625

 

$0.71-$3.90

 

$

1.65

Options granted

558,000

 

$2.25-$3.62

 

$

2.60

Options exercised

(163,500)

 

$0.71-$1.04

 

$

0.76

Options canceled or expired

(56,916)

 

$0.71-$3.62

 

$

2.49

Options outstanding at May 31, 2019

1,476,209

 

$0.82-$3.90

 

$

2.07


The weighted average fair value of options granted during 2019 and 2018 was $2.60 and $3.63, respectively. The aggregate intrinsic value of options exercised during 2019 and 2018 was approximately $364,000 and $87,000, respectively. The aggregate intrinsic value of options outstanding at May 31, 2019 and 2018 was approximately $808,000 and $2,755,000, respectively. The aggregate intrinsic value of options vested and exercisable at May 31, 2019 and 2018 was approximately $685,000 and $1,749,000, respectively.


Number of non-vested stock options included in table above is as follows:  


     

STOCK OPTIONS

WEIGHTED AVERAGE

AVERAGE

GRANT DATE

FAIR VALUE

     
     
 

NUMBER OF

SHARES

 
 

 

Nonvested shares at May 31, 2018

583,000

 

$

2.34

Granted

558,000

 

$

2.60

Vested/Exercised

(331,500)

 

$

2.34

Forfeited

(39,916)

 

$

3.08

Nonvested shares at May 31, 2019

769,584

 

$

2.49


At May 31, 2019, total compensation cost related to non-vested stock option awards not yet recognized totaled approximately $332,000. The weighted-average period over which this amount is expected to be recognized is 2.31 years. The weighted average remaining contractual term of options that were exercisable at May 31, 2019 was 4.93 years.


The following summarizes information about all of the Company's stock options outstanding at May 31, 2019. These options are comprised of those granted under the 2010, 2014 and 2017 plans.


   

WEIGHTED

 AVERAGE

 REMAINING

 CONTRACTUAL

LIFE IN YEARS

     
   

WEIGHTED

 AVERAGE

EXERCISE

 PRICE

NUMBER

 EXERCISABLE

AT MAY 31,

2019

 
 

NUMBER

 OUTSTANDING

May 31, 2019

WEIGHTED

 AVERAGE

EXERCISE PRICE

RANGE OF

EXERCISE PRICES

           $ 0.82

295,375

5.72

$ 0.82

283,375

$ 0.82

$ 0.85-$ 1.04

47,500

1.42

$ 1.02

 35,500

$ 1.02

$ 1.20-$ 1.61

330,000

6.56

$ 1.26

233,750

$ 1.26

$ 2.25-$ 3.90

803,334

8.00

$ 2.93

154,000

$2.93


COMMON STOCK ACTIVITY


During the year ended May 31, 2019, options to purchase 163,500 shares of common stock were exercised at prices ranging from $0.71 to $1.04.  Total net proceeds to the Company were $121,790.


During the year ended May 31, 2018, options to purchase 34,750 shares of common stock were exercised at prices ranging from $0.71 to $1.04.  Total net proceeds to the Company were $27,436.


During the year ended May 31, 2019, the Company sold 625,677 shares of its common stock at prices ranging from $2.59 to $4.16 under its S-3 Registration Statement which resulted in gross proceeds of $1,847,662 and net proceeds to the Company of $1,776,575 after deducting commissions for each sale and legal, accounting and other fees related to the filing of the S-3.


During the year ended May 31, 2018, the Company sold 342,088 shares of its common stock at prices ranging from $3.73 to $4.74 under its S-3 Registration Statement which resulted in gross proceeds of $1,379,226 and net proceeds to the Company of $1,275,933 (after receipt of subscriptions receivable at May 31, 2018) after deducting commissions for each sale and the initial legal and accounting fees related to the filing of the S-3. The subscriptions receivable of $9,062 was collected on June 4, 2018.